join retatrutide trial 💉 may be redefining obesity treatment. New data from TRIUMPH-1 showed: 🔥 ~28% average weight loss over 80 weeks 🔥 >30% weight loss in nearly half of participant #ObesityMedicine #Retatrutide #GLP1 #CardioMetabolic Retatrutide Phase 2: Type 2

Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas

This typically means switching to a stronger medication or making dietary or exercise changes, although these measures do not always resolve the plateau

Researchers note that the consistency of effects across multiple substances and outcomes provides a strong rationale for dedicated clinical trials

Vijay S, Brassier A, Ghosh A, Fecarotta S, Abel F, Marulkar S, Jones SA

Outcomes: Incidence of 13 obesity-related cancers (bladder, colorectal, kidney, breast, endometrial, thyroid, pancreatic, meningioma, liver, upper gastrointestinal, ovarian, multiple myeloma, and prostate) and lung cancer